Impression HARMONY Alliance, presented at the exhibition during the 1st European Alliance for Personalised Medicine Congress 2017 on 27-30 November 2017 in Belfast, Ireland. See more at www.harmony-alliance.eu HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

1. PATIENTS affected by Hematologic
Malignancies still have unmet needs.
We will address their urgent unmet
needs, such as faster diagnosis and
personalized therapies.
By using BIG DATA
SHARING among all
relevant stakeholders
involved, HARMONY
aims to improve
patient outcomes.

2. Introducing the HARMONY Alliance
A pan-European IMI project uniting and aligning healthcare system
stakeholders and key opinion leaders in the field of HM.
The first and largest Public Private Partnership in Hematology.
The largest project within the
IMI Big Data for Better Outcomes
(BD4BO) programme.
WHO
WE ARE
A high-quality multidisciplinary sources Big Data Platform that integrates
outcome measures and endpoint definitions for HMs.
Tools to empower clinicians and other Healthcare system stakeholders to
improve decision-making.
WE
OFFER

3. Addressing the need
to harmonize outcome
measures and endpoint
definitions for HMs at
a European level.

4. The HARMONY approach
• Collect, share and harmonize Big Data from high-quality
multidisciplinary sources.
• Assess and integrate a large amount of molecular data.
• Enable identification of novel pathways for drug
development.
• Generate evidence to encourage healthcare systems to
pay particular attention to the value of healthcare and to
improve outcomes.
• Facilitate drug development pipelines and accelerate
the “bench-to-bedside” process in drug development.
• Empower clinicians, policy makers and payers to
improve decision-making and optimize care for patients
with HM's.
• Generate multi stakeholder activities.

5. European Network of
Excellence for Big Data in
Hematology, consisting of
51public and private partners.

6. We believe that better therapy access
and improved care for patients
with various hematologic
malignancies (HMs) can be provided
by empowering clinicians, patients
and policy stakeholders.

7. European Network of
Excellence for Big Data in
Hematology, consisting of
51public and private partners.

8. Our focus is three-fold:
 offering an ethical and legal framework on the use of
medical data,
 analyzing the first data on the platform,
 and defining standard sets of outcomes.

9. European Network of
Excellence for Big Data in
Hematology, consisting of
51public and private partners.

10. We trust that, by making use of today’s Big Data
technologies, we can accelerate more efficient drug
development, regulatory evaluation, access appraisal,
and treatment strategies.

11. Addressing the need
to harmonize outcome
measures and endpoint
definitions for HMs at
a European level.

12. A European Network of Excellence
for Big Data in Hematology,
consisting of 51 partners.
Funded by the Innovative
Medicines Initiative.

13. European Network of
Excellence for Big Data in
Hematology, consisting of
51public and private partners.

14. Our goal is unlocking valuable knowledge on hematologic
malignancies (HMs). We are determined to create and
implement new treatment strategies based on big data
technologies to benefit society.

15. Funded through the Innovative
Medicines Initiative (IMI),
Europe's largest public-private
initiative aiming to speed up the
development of better and safer
medicines for patients.

16. 40 Million Euro
2017 – 2022
IMI2 BD4BO
Big Data for Better Outcomes